[Cardiac valvulopathy and dopamine agonist].
BACKGROUND
To assess the possible relationship between treatment with dopamine agonists and cardiac fibrotic valvulopathy in Parkinson's disease, a systematic review of published articles describing this association was performed.


METHODS
Cardiac valvulopathy has been described in parkinsonian patients taking pergolide, and in a few isolated cases treated with cabergoline or bromocriptine.


RESULTS
Until now, no cases of valvulopathy related to non-ergot dopamine agonists have been reported.


CONCLUSIONS
Cumulative dose and duration of treatment are likely risk factors for development of valvulopathy. In some cases, the discontinuation of ergotic dopamine agonists was followed by improvement of valve regurgitation.
Grandas
F
F
Servicio de Neurologia, Hospital General Universitario Gregorio Marañon, Madrid, Spain. frandasp@meditex.es
D000978:Antiparkinson Agents / Q000009:adverse effects*; D035843:Biomedical Research; D018491:Dopamine Agonists / Q000009:adverse effects*; D005355:Fibrosis / Q000139:chemically induced; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006351:Heart Valves / Q000473:pathology*; D006801:Humans; D010479:Pergolide / Q000009:adverse effects*
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D010479:Pergolide